EA202092828A1 - Антигенный вариант вируса varicella zoster и его применение - Google Patents

Антигенный вариант вируса varicella zoster и его применение

Info

Publication number
EA202092828A1
EA202092828A1 EA202092828A EA202092828A EA202092828A1 EA 202092828 A1 EA202092828 A1 EA 202092828A1 EA 202092828 A EA202092828 A EA 202092828A EA 202092828 A EA202092828 A EA 202092828A EA 202092828 A1 EA202092828 A1 EA 202092828A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigenic variant
zoster virus
varicella zoster
vaccine
application
Prior art date
Application number
EA202092828A
Other languages
English (en)
Inventor
Хио Дзунг Нам
Га Юнг Дзи
Эюнми Ким
Original Assignee
Могам Инститьют Фор Байомедикал Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Могам Инститьют Фор Байомедикал Рисерч filed Critical Могам Инститьют Фор Байомедикал Рисерч
Publication of EA202092828A1 publication Critical patent/EA202092828A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к антигенному варианту и его применению, где антигенный вариант представляет собой белок из поверхностных белков (gE) вируса Varicella zoster, проявляющий высокий уровень экспрессии и высокую иммуногенность, и таким образом, при использовании антигенного варианта в качестве вакцинной композиции данная вакцина имеет более высокую безопасность по сравнению с живой противовирусной вакциной, антигенный вариант демонстрирует более высокий уровень экспрессии в клетке-хозяине по сравнению с другими антигенами и, таким образом, пригоден в качестве вакцины для профилактики или лечения ветряной оспы или опоясывающего лишая, вызванных вирусом Varicella zoster.
EA202092828A 2018-05-23 2019-05-22 Антигенный вариант вируса varicella zoster и его применение EA202092828A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180058219 2018-05-23
PCT/KR2019/006113 WO2019225962A1 (ko) 2018-05-23 2019-05-22 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도

Publications (1)

Publication Number Publication Date
EA202092828A1 true EA202092828A1 (ru) 2021-03-11

Family

ID=68616069

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092828A EA202092828A1 (ru) 2018-05-23 2019-05-22 Антигенный вариант вируса varicella zoster и его применение

Country Status (19)

Country Link
US (1) US11642408B2 (ru)
EP (1) EP3812394A4 (ru)
JP (1) JP7247226B2 (ru)
KR (1) KR20210006460A (ru)
CN (1) CN112189017A (ru)
AU (1) AU2019272184B2 (ru)
BR (1) BR112020023642A2 (ru)
CA (1) CA3100462A1 (ru)
CO (1) CO2020015167A2 (ru)
EA (1) EA202092828A1 (ru)
IL (1) IL278892A (ru)
MA (1) MA51945B2 (ru)
MX (1) MX2020012469A (ru)
MY (1) MY195490A (ru)
PE (1) PE20201415A1 (ru)
PH (1) PH12020552009A1 (ru)
UA (1) UA126460C2 (ru)
WO (1) WO2019225962A1 (ru)
ZA (1) ZA202006956B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102270048B1 (ko) 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113683704B (zh) * 2021-07-28 2023-05-30 安徽智飞龙科马生物制药有限公司 一种水痘-带状疱疹病毒r-gE融合蛋白、重组水痘-带状疱疹疫苗及其制备方法和应用
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023122774A1 (en) 2021-12-23 2023-06-29 Dynavax Technologies Corporation Immunogenicity of a cpg-adjuvanted herpes zoster vaccine
CN116655748A (zh) * 2023-02-28 2023-08-29 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
CN117683121B (zh) * 2024-01-30 2024-04-16 北京百普赛斯生物科技股份有限公司 抗水痘-带状疱疹病毒抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
DK0504388T3 (da) * 1990-10-04 2000-12-27 Res Corp Technologies Inc Varicel-zoster-virus-antigen
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
WO2006128026A2 (en) 2005-05-26 2006-11-30 The United States Of America As Represented By Thesecretary, Dept. Of Health And Human Services National Institutes Of Health Cellular receptor for varicella-zoster virus, methods of inhibiting spread of varicella-zoster and methods of increasing stability and infectivity of the virus
US9243041B2 (en) * 2011-01-31 2016-01-26 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
JP2014508522A (ja) 2011-02-24 2014-04-10 モガム バイオテクノロジー リサーチ インスティチュート 新規な水痘帯状疱疹ウイルス株及びそれを用いた水痘及び帯状疱疹ウイルスワクチン
CN102517302A (zh) * 2011-12-28 2012-06-27 中国人民解放军军事医学科学院野战输血研究所 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
CN105669838B (zh) * 2014-12-04 2020-10-16 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
CA2970840A1 (en) 2014-12-18 2016-06-23 Glaxosmithkline Biologicals S.A. Vaccine composition comprising truncated varicella zoster virus glycoprotein e antigen
AU2015384281B2 (en) * 2015-02-25 2018-11-22 Mogam Institute For Biomedical Research Novel antibody binding to TFPI and composition comprising the same
JP6367783B2 (ja) 2015-11-26 2018-08-01 田中貴金属工業株式会社 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置

Also Published As

Publication number Publication date
MX2020012469A (es) 2021-02-09
PE20201415A1 (es) 2020-12-07
WO2019225962A1 (ko) 2019-11-28
ZA202006956B (en) 2022-03-30
CO2020015167A2 (es) 2020-12-21
IL278892A (en) 2021-01-31
AU2019272184A1 (en) 2021-01-14
MA51945A1 (fr) 2021-09-30
MA51945B2 (fr) 2023-08-31
MY195490A (en) 2023-01-26
AU2019272184B2 (en) 2022-01-27
JP7247226B2 (ja) 2023-03-28
US20210187099A1 (en) 2021-06-24
KR20210006460A (ko) 2021-01-18
PH12020552009A1 (en) 2021-06-14
EP3812394A4 (en) 2022-03-23
EP3812394A1 (en) 2021-04-28
US11642408B2 (en) 2023-05-09
CA3100462A1 (en) 2019-11-28
JP2021525079A (ja) 2021-09-24
CN112189017A (zh) 2021-01-05
UA126460C2 (uk) 2022-10-05
BR112020023642A2 (pt) 2021-02-17

Similar Documents

Publication Publication Date Title
EA202092828A1 (ru) Антигенный вариант вируса varicella zoster и его применение
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
PH12018500855A1 (en) Herpes simplex virus vaccine
EA201891001A1 (ru) Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
MX2018004127A (es) Anticuerpos que neutralizan potencialmente el virus de hepatitis b y usos de los mismos.
EA201990017A1 (ru) Антитела к миостатину и способы их применения
EA202191622A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
CO2017007105A2 (es) Nuevos virus de tilapia
EA202090049A1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
EA201892702A1 (ru) Стабилизированные f-белки rsv до слияния
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
MX2021005345A (es) Composiciones y metodos.
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
MX366263B (es) Parvovirus porcino 5b, metodos de uso y vacuna.
WO2015144732A3 (en) Uses of parasite macrophage migration inhibitory factors
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201591747A1 (ru) Иммуногенный пептидный конъюгат и способ индуцирования терапевтического гуморального ответа против вируса гриппа с его применением
MX2016009952A (es) Proteinas y antigenos del virus de diarrea epidemica porcino (pedv).